Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Ourania Tatsis Sells 466 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 466 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total transaction of $214,560.38. Following the completion of the sale, the executive vice president owned 51,436 shares of the company’s stock, valued at approximately $23,682,677.48. This represents a 0.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ourania Tatsis also recently made the following trade(s):

• On Wednesday, January 7th, Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $474.99, for a total transaction of $2,137,455.00.

Vertex Pharmaceuticals Stock Up 0.8%

VRTX stock traded up $3.78 during trading on Thursday, reaching $465.02. The stock had a trading volume of 1,816,913 shares, compared to its average volume of 1,542,259. The company has a market capitalization of $117.98 billion, a price-to-earnings ratio of 32.79 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The company’s 50 day moving average is $459.11 and its two-hundred day moving average is $427.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VRTX. Brighton Jones LLC increased its stake in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after acquiring an additional 579 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Vertex Pharmaceuticals by 16.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 126,540 shares of the pharmaceutical company’s stock valued at $57,216,000 after purchasing an additional 18,011 shares in the last quarter. MGO One Seven LLC grew its stake in Vertex Pharmaceuticals by 2.4% in the 2nd quarter. MGO One Seven LLC now owns 1,822 shares of the pharmaceutical company’s stock worth $811,000 after buying an additional 43 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Vertex Pharmaceuticals by 1.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 17,294 shares of the pharmaceutical company’s stock worth $7,699,000 after buying an additional 272 shares during the last quarter. Finally, Community Bank N.A. raised its position in shares of Vertex Pharmaceuticals by 58.8% during the 2nd quarter. Community Bank N.A. now owns 1,964 shares of the pharmaceutical company’s stock valued at $874,000 after buying an additional 727 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue and outlook: Vertex reported solid Q4 revenue (~$3.19B) with management forecasting 2026 revenue roughly in line with street expectations and reiterating growth from its cystic fibrosis portfolio and newer medicines — a near-term reassurance for revenue trajectory. Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
• Positive Sentiment: Pipeline expansion: Vertex announced a partnership with WuXi to broaden its autoimmune program beyond cystic fibrosis — a strategic move that supports longer-term growth expectations and analyst bullishness on pipeline upside. Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis
• Neutral Sentiment: Guidance roughly in line: The company updated FY‑2026 revenue guidance to about $13.0–13.1B (in line with consensus); EPS guidance details were limited in the release, leaving investors focused on execution rather than a big surprise. Vertex Q4 press release / slides
• Neutral Sentiment: Analyst momentum/valuation coverage: Multiple analysts maintain bullish price targets (median target near $545), and commentary that VRTX is a long‑term momentum/valuation story likely helped sentiment despite mixed line‑items. Why Vertex is a Top Momentum Stock for the Long-Term
• Negative Sentiment: Small EPS miss and mixed beat: Reported EPS was $5.03 (slightly below consensus ~$5.05–5.07) — a modest disappointment even as revenue was essentially in-line/solid; some outlets noted the stock dipped on the headline EPS number. Vertex Q4 Earnings Miss Estimates (Zacks)
• Negative Sentiment: Insider selling: Several senior executives (multiple EVPs and the CAO) sold shares around Feb. 11 — a visible round of insider selling that can concern some investors even if sales may be routine or for diversification. QuiverQuant summary including insider trades

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Leerink Partners upped their price objective on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research note on Monday, December 29th. Barclays upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $414.00 to $606.00 in a research note on Tuesday, January 27th. Evercore increased their price target on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Finally, Stifel Nicolaus lowered their price objective on Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $522.68.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.